Cancer Research Center, School of Medicine, Xiamen University, Xiamen, P.R. China.
Department of Respiratory Medicine, Fujian Provincial Hospital, Fuzhou, Fujian, P.R. China.
Cancer Res. 2021 Dec 1;81(23):5904-5918. doi: 10.1158/0008-5472.CAN-21-0980. Epub 2021 Oct 15.
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4α is abnormally enriched in IMA, but the potential of HNF4α to be a therapeutic target for IMA remains unknown. Here, we report that P2 promoter-driven HNF4α expression promotes IMA growth and metastasis. Mechanistically, HNF4α transactivated lncRNA BC200, which acted as a scaffold for mRNA binding protein FMR1. BC200 promoted the ability of FMR1 to bind and regulate stability of cancer-related mRNAs and HNF4α mRNA, forming a positive feedback circuit. Mycophenolic acid, the active metabolite of FDA-approved drug mycophenolate mofetil, was identified as an HNF4α antagonist exhibiting anti-IMA activities and . This study reveals the role of a HNF4α-BC200-FMR1-positive feedback loop in promoting mRNA stability during IMA progression and metastasis, providing a targeted therapeutic strategy for IMA. SIGNIFICANCE: Growth and metastatic progression of invasive mucinous lung adenocarcinoma can be restricted by targeting HNF4α, a critical regulator of a BC200-FMR1-mRNA stability axis.
侵袭性黏液性腺癌(IMA)是肺腺癌的一种亚型,具有很强的侵袭能力。IMA 常携带“不可用药”的 KRAS 突变,这凸显了寻找新的分子靶点和治疗方法的必要性。核受体 HNF4α 在 IMA 中异常富集,但 HNF4α 是否可以成为 IMA 的治疗靶点尚不清楚。在这里,我们报告 P2 启动子驱动的 HNF4α 表达促进了 IMA 的生长和转移。在机制上,HNF4α 可反式激活 lncRNA BC200,后者作为 mRNA 结合蛋白 FMR1 的支架。BC200 增强了 FMR1 结合和调节与癌症相关的 mRNA 和 HNF4α mRNA 稳定性的能力,形成正反馈回路。霉酚酸,FDA 批准的药物霉酚酸酯的活性代谢物,被鉴定为 HNF4α 拮抗剂,具有抗 IMA 活性。这项研究揭示了在 IMA 进展和转移过程中,HNF4α-BC200-FMR1-正反馈环在促进 mRNA 稳定性方面的作用,为 IMA 提供了一种靶向治疗策略。意义:通过靶向关键调节因子 HNF4α,可限制侵袭性黏液性腺癌的生长和转移进展,HNF4α 是 BC200-FMR1-mRNA 稳定性轴的关键调节因子。